SAVIMS

SAVIMS logo white
Menu

Resource Type

Nutritional supplements, Other scientific evidence, Resource Type, Treatment

The Health Benefits of Tocotrienols: An Underappreciated Vitamin E Isomer

| | Nutritional supplements, Other scientific evidence, Resource Type, Treatment

Reference: Musa, A. F. (2021). Tocotrienol: An underrated isomer of vitamin E in health and diseases. In Vitamin E in Health and Disease – Interactions, Diseases and Health Aspects. IntechOpen. https://doi.org/10.5772/intechopen.96451 Summary: This chapter explores tocotrienols, an often-overlooked form of vitamin E, highlighting their significant health benefits. Tocotrienols, found abundantly in palm oil, possess superior […]

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of Janssen’s Ad26.COV2.S Vaccine for COVID-19

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: FDA. (2021). Vaccines and related biological products advisory committee meeting: February 26, 2021. Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. FDA Briefing Document. Summary: The FDA briefing document details the Emergency Use Authorization (EUA) request submitted by Janssen Biotech for the Ad26.COV2.S vaccine aimed at preventing COVID-19. This single-dose adenovirus vector vaccine demonstrated

COVID-19, Ivermectin, News, Other scientific evidence, Treatment, Viral illnesses

BIRD Recommendation on Ivermectin for Covid-19

| | COVID-19, Ivermectin, News, Other scientific evidence, Treatment, Viral illnesses

Reference: British Ivermectin Recommendation Development. (2021). The BIRD recommendation on the use of ivermectin for Covid-19: Executive summary. Proceedings and conclusions of the British Ivermectin Recommendation Development meeting. Summary: The British Ivermectin Recommendation Development (BIRD) meeting, held on 20th February 2021 in Bath, aimed to evaluate ivermectin’s efficacy in treating and preventing Covid-19, especially in

COVID-19, Covid-19 vaccines, Ethics, Other scientific evidence, Reference Library, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Case Investigation Form for AEFI and AESI

| | COVID-19, Covid-19 vaccines, Ethics, Other scientific evidence, Reference Library, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Author. (2021). Case investigation form for AEFI serious, severe, cluster, AESI for all vaccines including COVID-19. Retrieved from [insert URL if available] Summary: The document is a Case Investigation Form designed to report Adverse Events Following Immunisation (AEFI) and Adverse Events of Special Interest (AESI) for all vaccines, including COVID-19. It is intended for

COVID-19, Ivermectin, Other scientific evidence, Treatment, Viral illnesses

Efficacy of Ivermectin in COVID-19 Treatment FLCCC

| | COVID-19, Ivermectin, Other scientific evidence, Treatment, Viral illnesses

Reference: Kory, P., Meduri, G. U., Iglesias, J., Varon, J., & Marik, P. E. (2021). Review of the emerging evidence supporting the efficacy of ivermectin in the prophylaxis and treatment of COVID-19. Front-Line COVID-19 Critical Care Alliance. Summary: This article by the Front Line COVID-19 Critical Care Alliance reviews the growing evidence supporting ivermectin’s effectiveness

Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

FDA-Approved Prescription Drugs Withdrawn for Safety Reasons

| | Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

Reference: ProCon.org. (2021). FDA-approved prescription drugs later pulled from the market by the FDA. Retrieved from https://prescriptiondrugs.procon.org/fda-approved-prescription-drugs-later-pulled-from-the-market/ Summary: The article by ProCon.org discusses various prescription drugs that were once FDA-approved but later withdrawn from the market due to safety concerns. The FDA’s role in drug removal is highlighted, emphasising that drugs are typically pulled when

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Quarterly Update on COVID-19 Adverse Events of Special Interest

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Law, B. (2020). Priority List of COVID-19 Adverse Events of Special Interest: Quarterly Update December 2020. Safety Platform for Emergency Vaccines (SPEAC). Summary: The report provides a quarterly update on the Safety Platform for Emergency Vaccines (SPEAC) regarding Adverse Events of Special Interest (AESI) related to COVID-19. The December 2020 update includes three new

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Prophylaxis and Early Treatment of COVID-19: The I-MASK+ Protocol

| | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2021). I-MASK+ prophylaxis & early outpatient treatment protocol for COVID-19. Retrieved from www.flccc.net Summary: The FLCCC Alliance’s I-MASK+ protocol provides guidelines for the prophylaxis and early outpatient treatment of COVID-19. It recommends the use of Ivermectin, along with Vitamin D3, Vitamin C, Quercetin, Zinc, Melatonin, and Aspirin for high-risk individuals and post-exposure

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Multifaceted Sequential Multidrug Treatment for Early High-Risk COVID-19 Patients

| | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Peer-reviewed evidence, Resource Type, Treatment, Viral illnesses

Reference: McCullough, P. A., Alexander, P. E., Armstrong, R., Arvinte, C., Bain, A. F., Bartlett, R. P., … & Zelenko, V. (2020). Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 21(4), 517–530. https://doi.org/10.31083/j.rcm.2020.04.264 Summary: The article discusses a comprehensive approach to treat early ambulatory high-risk COVID-19

COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Evaluation of COVID-19 Vaccine Safety Profile

| | COVID-19, Covid-19 vaccines, Genetic vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Wu, Q., Dudley, M. Z., Chen, X., Bai, X., Dong, K., Zhuang, T., Salmon, D., & Yu, H. (2021). Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Medicine, 19, 173. https://doi.org/10.1186/s12916-021-02059-5 Summary: This article presents a rapid review and meta-analysis of the safety profiles of COVID-19 vaccines. It highlights public

Scroll to Top